Our recent studies identified the class I HDAC inhibitor entinostat (SNDX-275 or MS-275) as a special agent to selectively inhibit erbB3 leading to a dramatic reduction of P-Akt in erbB2-positive breast cancer cells [53]. This evidence concerns the gene ERBB2 and breast carcinoma.